Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 760

1.

Correction to: On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.

Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.

Rheumatol Int. 2019 Feb 5. doi: 10.1007/s00296-018-4232-9. [Epub ahead of print]

PMID:
30721326
2.

Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 systemic sclerosis criteria.

Boonstra M, Ninaber MK, Ajmone Marsan N, Huizinga TWJ, Scherer HU, de Vries-Bouwstra JK.

Rheumatology (Oxford). 2019 Jan 27. doi: 10.1093/rheumatology/kez005. [Epub ahead of print] No abstract available.

PMID:
30690619
3.

In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response.

de Moel EC, Derksen VFAM, Trouw LA, Bang H, Collée G, Lard LR, Ramiro S, Huizinga TWJ, Allaart CF, Toes REM, van der Woude D.

Arthritis Res Ther. 2019 Jan 18;21(1):28. doi: 10.1186/s13075-019-1815-0.

4.

Laboratory and Neuroimaging Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: Where Do We Stand, Where To Go?

Magro-Checa C, Steup-Beekman GM, Huizinga TW, van Buchem MA, Ronen I.

Front Med (Lausanne). 2018 Dec 4;5:340. doi: 10.3389/fmed.2018.00340. eCollection 2018. Review.

5.

Are serum autoantibodies associated with brain changes in systemic lupus erythematosus? MRI data from the Leiden NP-SLE cohort.

Magro-Checa C, Kumar S, Ramiro S, Beaart-van de Voorde LJ, Eikenboom J, Ronen I, de Bresser J, van Buchem MA, Huizinga TW, Steup-Beekman GM.

Lupus. 2018 Dec 8:961203318816819. doi: 10.1177/0961203318816819. [Epub ahead of print]

6.

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.

de Moel EC, Rozeman EA, Kapiteijn EH, Verdegaal EME, Grummels A, Bakker JA, Huizinga TWJ, Haanen JB, Toes REM, van der Woude D.

Cancer Immunol Res. 2019 Jan;7(1):6-11. doi: 10.1158/2326-6066.CIR-18-0245. Epub 2018 Nov 13.

PMID:
30425107
7.

On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.

Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.

Rheumatol Int. 2018 Dec;38(12):2225-2231. doi: 10.1007/s00296-018-4173-3. Epub 2018 Oct 20. Erratum in: Rheumatol Int. 2019 Feb 5;:.

PMID:
30341453
8.

Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial.

Kloppenburg M, Ramonda R, Bobacz K, Kwok WY, Elewaut D, Huizinga TWJ, Kroon FPB, Punzi L, Smolen JS, Vander Cruyssen B, Wolterbeek R, Verbruggen G, Wittoek R.

Ann Rheum Dis. 2018 Dec;77(12):1757-1764. doi: 10.1136/annrheumdis-2018-213202. Epub 2018 Oct 3.

PMID:
30282670
9.

Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis.

Dekkers JS, Bergstra SA, Chopra A, Tikly M, Fonseca JE, Salomon-Escoto K, Huizinga TWJ, van der Woude D.

Rheumatology (Oxford). 2019 Jan 1;58(1):149-153. doi: 10.1093/rheumatology/key263.

PMID:
30204896
10.

To what extent do autoantibodies help to identify high-risk patients in systemic sclerosis?

Boonstra M, Mertens BJA, Bakker JA, Ninaber MK, Ajmone Marsan N, van der Helm-van Mil AHM, Scherer HU, Huizinga TWJ, de Vries-Bouwstra JK.

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):109-117. Epub 2018 Jul 18.

PMID:
30148428
11.

Anti-Carbamylated Protein Antibodies and Higher Baseline Disease Activity in Rheumatoid Arthritis-A Replication Study in Three Cohorts: Comment on the Article by Truchetet et al.

Derksen VFAM, Trouw LA, Huizinga TWJ, van der Helm-van Mil AHM, Knevel R, Westerlind H, Saevarsdottir S, Ajeganova S, van der Woude D.

Arthritis Rheumatol. 2018 Dec;70(12):2096-2097. doi: 10.1002/art.40678. Epub 2018 Oct 27. No abstract available.

PMID:
30058116
12.

In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission.

de Moel EC, Derksen VFAM, Trouw LA, Bang H, Goekoop-Ruiterman YPM, Steup-Beekman GM, Huizinga TWJ, Allaart CF, Toes REM, van der Woude D.

Ann Rheum Dis. 2018 Dec;77(12):1836-1838. doi: 10.1136/annrheumdis-2018-213823. Epub 2018 Jul 25. No abstract available.

PMID:
30045852
13.

MR signal intensity: staying on the bright side in MR image interpretation.

Bloem JL, Reijnierse M, Huizinga TWJ, van der Helm-van Mil AHM.

RMD Open. 2018 Jun 20;4(1):e000728. doi: 10.1136/rmdopen-2018-000728. eCollection 2018.

14.

Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis.

Akdemir G, Markusse IM, Bergstra SA, Goekoop RJ, Molenaar ET, van Groenendael JHLM, Kerstens PJSM, Lems WF, Huizinga TWJ, Allaart CF.

RMD Open. 2018 May 20;4(1):e000649. doi: 10.1136/rmdopen-2018-000649. eCollection 2018.

15.

The anti-carbamylated protein antibody response is of overall low avidity despite extensive isotype switching.

van Delft MAM, Verheul MK, Burgers LE, Rantapää-Dahlqvist S, van der Helm-van Mil AHM, Huizinga TWJ, Toes REM, Trouw LA.

Rheumatology (Oxford). 2018 Sep 1;57(9):1583-1591. doi: 10.1093/rheumatology/key135.

PMID:
29846726
16.

Triple Positivity for Anti-Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti-Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis: Implications for Very Early Identification of At-Risk Individuals.

Verheul MK, Böhringer S, van Delft MAM, Jones JD, Rigby WFC, Gan RW, Holers VM, Edison JD, Deane KD, Janssen KMJ, Westra J, Brink M, Rantapää-Dahlqvist S, Huizinga TWJ, van der Helm-van Mil AHM, van der Woude D, Toes REM, Trouw LA.

Arthritis Rheumatol. 2018 Nov;70(11):1721-1731. doi: 10.1002/art.40562. Epub 2018 Sep 16.

PMID:
29781231
17.

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.

Genovese MC, van Adelsberg J, Fan C, Graham NMH, van Hoogstraten H, Parrino J, Mangan EK, Spindler A, Huizinga TWJ, van der Heijde D; EXTEND study investigators.

Rheumatology (Oxford). 2018 Aug 1;57(8):1423-1431. doi: 10.1093/rheumatology/key121.

18.

Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study.

Jansen DTSL, Emery P, Smolen JS, Westhovens R, Le Bars M, Connolly SE, Ye J, Toes REM, Huizinga TWJ.

RMD Open. 2018 Mar 30;4(1):e000564. doi: 10.1136/rmdopen-2017-000564. eCollection 2018.

19.

Comment on "Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis".

Volkov M, Dekkers J, Loos BG, Bizzarro S, Huizinga TWJ, Praetorius HA, Toes REM, van der Woude D.

Sci Transl Med. 2018 Mar 21;10(433). pii: eaan8349. doi: 10.1126/scitranslmed.aan8349.

PMID:
29563322
20.

Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes.

de Moel EC, Derksen VFAM, Stoeken G, Trouw LA, Bang H, Goekoop RJ, Speyer I, Huizinga TWJ, Allaart CF, Toes REM, van der Woude D.

Arthritis Res Ther. 2018 Feb 26;20(1):33. doi: 10.1186/s13075-018-1520-4.

21.

The B cell response to citrullinated antigens in the development of rheumatoid arthritis.

Scherer HU, Huizinga TWJ, Krönke G, Schett G, Toes REM.

Nat Rev Rheumatol. 2018 Mar;14(3):157-169. doi: 10.1038/nrrheum.2018.10. Epub 2018 Feb 8. Review.

PMID:
29416134
22.

Fc gamma receptor binding profile of anti-citrullinated protein antibodies in immune complexes suggests a role for FcγRI in the pathogenesis of synovial inflammation.

Kempers AC, Nejadnik MR, Rombouts Y, Ioan-Facsinay A, van Oosterhout M, Jiskoot W, Huizinga TWJ, Toes REM, Scherer HU.

Clin Exp Rheumatol. 2018 Mar-Apr;36(2):284-293. Epub 2018 Jan 15.

23.

Depression and anxiety associate with less remission after 1 year in rheumatoid arthritis.

Boer AC, Huizinga TWJ, van der Helm-van Mil AHM.

Ann Rheum Dis. 2019 Jan;78(1):e1. doi: 10.1136/annrheumdis-2017-212867. Epub 2018 Jan 8. No abstract available.

PMID:
29311145
24.

Evaluation of the joint distribution at disease presentation of patients with rheumatoid arthritis: a large study across continents.

Bergstra SA, Chopra A, Saluja M, Vega-Morales D, Govind N, Huizinga TWJ, van der Helm-van Mil A.

RMD Open. 2017 Dec 10;3(2):e000568. doi: 10.1136/rmdopen-2017-000568. eCollection 2017.

25.

Dosing down with biologic therapies: a systematic review and clinicians' perspective.

Edwards CJ, Fautrel B, Schulze-Koops H, Huizinga TWJ, Kruger K.

Rheumatology (Oxford). 2018 Mar 1;57(3):589. doi: 10.1093/rheumatology/kex503. No abstract available.

26.

Antisense Long Non-Coding RNAs Are Deregulated in Skin Tissue of Patients with Systemic Sclerosis.

Messemaker TC, Chadli L, Cai G, Goelela VS, Boonstra M, Dorjée AL, Andersen SN, Mikkers HMM, van 't Hof P, Mei H, Distler O, Draisma HHM, Johnson ME, Orzechowski NM, Simms RW, Toes REM, Aarbiou J, Huizinga TW, Whitfield ML, DeGroot J, de Vries-Bouwstra J, Kurreeman F.

J Invest Dermatol. 2018 Apr;138(4):826-835. doi: 10.1016/j.jid.2017.09.053. Epub 2017 Nov 24.

27.

Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.

Bergstra SA, Allaart CF, van den Berg R, Chopra A, Govind N, Huizinga TWJ, Landewe RBM.

Arthritis Res Ther. 2017 Nov 22;19(1):258. doi: 10.1186/s13075-017-1468-9.

28.

An evidence-based approach to pre-pregnancy counselling for patients with systemic lupus erythematosus.

Teng YKO, Bredewold EOW, Rabelink TJ, Huizinga TWJ, Eikenboom HCJ, Limper M, Fritsch-Stork RDE, Bloemenkamp KWM, Sueters M.

Rheumatology (Oxford). 2018 Oct 1;57(10):1707-1720. doi: 10.1093/rheumatology/kex374. Review.

PMID:
29165607
29.

Preventing progression from arthralgia to arthritis: targeting the right patients.

van Steenbergen HW, da Silva JAP, Huizinga TWJ, van der Helm-van Mil AHM.

Nat Rev Rheumatol. 2018 Jan;14(1):32-41. doi: 10.1038/nrrheum.2017.185. Epub 2017 Nov 9. Review.

30.

Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study.

Akdemir G, Heimans L, Bergstra SA, Goekoop RJ, van Oosterhout M, van Groenendael JHLM, Peeters AJ, Steup-Beekman GM, Lard LR, de Sonnaville PBJ, Grillet BAM, Huizinga TWJ, Allaart CF.

Ann Rheum Dis. 2018 Jan;77(1):111-118. doi: 10.1136/annrheumdis-2017-211375. Epub 2017 Sep 28.

PMID:
28970207
31.

Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy.

Bergstra SA, Landewé RBM, Huizinga TWJ, Allaart CF.

Rheumatology (Oxford). 2017 Oct 1;56(10):1721-1728. doi: 10.1093/rheumatology/kex236.

PMID:
28957556
32.

Using a reference when defining an abnormal MRI reduces false-positive MRI results-a longitudinal study in two cohorts at risk for rheumatoid arthritis.

Boer AC, Burgers LE, Mangnus L, Ten Brinck RM, Nieuwenhuis WP, van Steenbergen HW, Reijnierse M, Huizinga TWJ, van der Helm van Mil AHM.

Rheumatology (Oxford). 2017 Oct 1;56(10):1700-1706. doi: 10.1093/rheumatology/kex235.

PMID:
28957551
33.

Do Comorbidities Play a Role in Hand Osteoarthritis Disease Burden? Data from the Hand Osteoarthritis in Secondary Care Cohort.

Damman W, Liu R, Kroon FPB, Reijnierse M, Huizinga TWJ, Rosendaal FR, Kloppenburg M.

J Rheumatol. 2017 Nov;44(11):1659-1666. doi: 10.3899/jrheum.170208. Epub 2017 Sep 15. Erratum in: J Rheumatol. 2019 Jan;46(1):118-119.

PMID:
28916548
34.

Rituximab in early systemic sclerosis.

Boonstra M, Meijs J, Dorjée AL, Marsan NA, Schouffoer A, Ninaber MK, Quint KD, Bonte-Mineur F, Huizinga TWJ, Scherer HU, de Vries-Bouwstra JK.

RMD Open. 2017 Jul 28;3(2):e000384. doi: 10.1136/rmdopen-2016-000384. eCollection 2017.

35.

Functional limitations in the phase of clinically suspect arthralgia are as serious as in early clinical arthritis; a longitudinal study.

Ten Brinck RM, van Steenbergen HW, Mangnus L, Burgers LE, Reijnierse M, Huizinga TW, van der Helm-van Mil AH.

RMD Open. 2017 Jun 29;3(1):e000419. doi: 10.1136/rmdopen-2016-000419. eCollection 2017.

36.

B-cell receptor sequencing of anti-citrullinated protein antibody (ACPA) IgG-expressing B cells indicates a selective advantage for the introduction of N-glycosylation sites during somatic hypermutation.

Vergroesen RD, Slot LM, Hafkenscheid L, Koning MT, van der Voort EIH, Grooff CA, Zervakis G, Veelken H, Huizinga TWJ, Rispens T, Scherer HU, Toes REM.

Ann Rheum Dis. 2018 Jun;77(6):956-958. doi: 10.1136/annrheumdis-2017-212052. Epub 2017 Aug 23. No abstract available.

PMID:
28835463
37.

The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients.

van Delft MAM, Verheul MK, Burgers LE, Derksen VFAM, van der Helm-van Mil AHM, van der Woude D, Huizinga TWJ, Toes REM, Trouw LA.

Arthritis Res Ther. 2017 Aug 15;19(1):190. doi: 10.1186/s13075-017-1392-z.

38.

Inflammatory genes TNFα and IL6 display no signs of increased H3K4me3 in circulating monocytes from untreated rheumatoid arthritis patients.

Messemaker TC, Mikkers HMM, Huizinga TW, Toes REM, van der Helm-van Mil AHM, Kurreeman F.

Genes Immun. 2017 Sep;18(3):191-196. doi: 10.1038/gene.2017.20. Epub 2017 Aug 10.

PMID:
28794503
39.

The extensive glycosylation of the ACPA variable domain observed for ACPA-IgG is absent from ACPA-IgM.

Kempers AC, Hafkenscheid L, Dorjée AL, Moutousidou E, van de Bovenkamp FS, Rispens T, Trouw LA, van Oosterhout M, Huizinga TW, Toes R, Scherer HU.

Ann Rheum Dis. 2018 Jul;77(7):1087-1088. doi: 10.1136/annrheumdis-2017-211533. Epub 2017 Jul 26. No abstract available.

PMID:
28747327
40.

Genomic Influences on Susceptibility and Severity of Rheumatoid Arthritis.

Knevel R, Huizinga TWJ, Kurreeman F.

Rheum Dis Clin North Am. 2017 Aug;43(3):347-361. doi: 10.1016/j.rdc.2017.04.002. Review.

PMID:
28711138
41.

Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis.

Eektimmerman F, Swen JJ, Böhringer S, Huizinga TW, Kooloos WM, Allaart CF, Guchelaar HJ.

Pharmacogenomics. 2017 Jul;18(10):945-953. doi: 10.2217/pgs-2017-0047. Epub 2017 Jun 22.

PMID:
28639493
42.

Differences in the symptomatic phase preceding ACPA-positive and ACPA-negative RA: a longitudinal study in arthralgia during progression to clinical arthritis.

Burgers LE, van Steenbergen HW, Ten Brinck RM, Huizinga TW, van der Helm-van Mil AH.

Ann Rheum Dis. 2017 Oct;76(10):1751-1754. doi: 10.1136/annrheumdis-2017-211325. Epub 2017 Jun 12.

PMID:
28606964
43.

Anti-citrullinated protein antibodies in the diagnosis of rheumatoid arthritis (RA): diagnostic performance of automated anti-CCP-2 and anti-CCP-3 antibodies assays.

Vos I, Van Mol C, Trouw LA, Mahler M, Bakker JA, Van Offel J, De Clerck L, Huizinga TW.

Clin Rheumatol. 2017 Jul;36(7):1487-1492. doi: 10.1007/s10067-017-3684-8. Epub 2017 Jun 3.

44.

Auto-antibodies and cancer in systemic sclerosis.

Boonstra M, Huizinga TWJ, de Vries-Bouwstra JK.

Autoimmun Rev. 2017 Aug;16(8):883-884. doi: 10.1016/j.autrev.2017.05.023. Epub 2017 May 29. No abstract available.

45.

The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical.

Boeters DM, Mangnus L, Ajeganova S, Lindqvist E, Svensson B, Toes REM, Trouw LA, Huizinga TWJ, Berenbaum F, Morel J, Rantapää-Dahlqvist S, van der Helm-van Mil AHM.

Arthritis Res Ther. 2017 May 31;19(1):115. doi: 10.1186/s13075-017-1324-y.

46.

Is optimising gout treatment the key to closing the mortality gap in gout patients?

Ten Brinck RM, de Moel EC, van der Pol JA, van Beest S, de Koning A, Huizinga TWJ.

Ann Rheum Dis. 2018 Jan;77(1):e2. doi: 10.1136/annrheumdis-2017-211638. Epub 2017 May 25. No abstract available.

PMID:
28546256
47.

Long-term mortality in patients with ST-segment elevation myocardial infarction is associated with anti-citrullinated protein antibodies.

Hermans MPJ, van der Velden D, Montero Cabezas JM, Putter H, Huizinga TWJ, Kuiper J, Toes REM, Schalij MJ, Wouter Jukema J, van der Woude D.

Int J Cardiol. 2017 Aug 1;240:20-24. doi: 10.1016/j.ijcard.2017.04.046. Epub 2017 Apr 25.

PMID:
28487154
48.

Protein array autoantibody profiles to determine diagnostic markers for neuropsychiatric systemic lupus erythematosus.

van der Meulen PM, Barendregt AM, Cuadrado E, Magro-Checa C, Steup-Beekman GM, Schonenberg-Meinema D, Van den Berg JM, Li QZ, Baars PA, Wouters D, Voskuyl AE, Ten Berge IRJM, Huizinga TWJ, Kuijpers TW.

Rheumatology (Oxford). 2017 Aug 1;56(8):1407-1416. doi: 10.1093/rheumatology/kex073.

PMID:
28460084
49.

Evaluation of the diagnostic accuracy of hand and foot MRI for early Rheumatoid Arthritis.

Nieuwenhuis WP, van Steenbergen HW, Mangnus L, Newsum EC, Bloem JL, Huizinga TWJ, le Cessie S, Reijnierse M, van der Helm-van Mil AHM.

Rheumatology (Oxford). 2017 Aug 1;56(8):1367-1377. doi: 10.1093/rheumatology/kex167.

PMID:
28460018
50.

The role of autoantibodies in the pathophysiology of rheumatoid arthritis.

Derksen VFAM, Huizinga TWJ, van der Woude D.

Semin Immunopathol. 2017 Jun;39(4):437-446. doi: 10.1007/s00281-017-0627-z. Epub 2017 Apr 27. Review.

Supplemental Content

Loading ...
Support Center